Short answer
CorMedix Inc. (CRMD) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Conference call discussed CorMedix’s financial results for quarter ended September 30, 2026.
CorMedix Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Conference call discussed CorMedix’s financial results for quarter ended September 30, 2026
- Full investor-call transcript furnished as Exhibit 99.1, containing management commentary and financial-results details
- Proposed acquisition of substantially all Heron assets remains subject to Heron stockholder approval and required regulatory clearances
- Transaction would issue CorMedix common stock to Heron through a private placement, creating potential shareholder dilution
- Management highlights four FDA-approved commercial brands and anticipated revenue diversification, synergies and earnings accretion as transaction rationale
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $54.5M, down from $104.3M, reflecting DefenCath pricing pressure after post-TDAPA transition
- DefenCath sales $17.2M, with dialysis utilization largely maintained at the $2.37 add-on rate
- Heron assets expected to add $125M-$150M revenue in pro forma 2027 and $45M-$60M annual operating synergies by end-2027
- FY2026 revenue guidance maintained at $325M-$345M, while adjusted EBITDA guidance narrowed to $130M-$140M
- 2027 DefenCath guidance deferred amid quarterly reimbursement uncertainty and ongoing Medicare Advantage contracting
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CorMedix Inc. 8-K filings
Get the next CRMD 8-K as it lands
Follow CRMD for push alerts, or ask the research agent what this filing means.